Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.

@article{Royce2017SurrogateEP,
  title={Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.},
  author={Trevor Joseph Royce and Ming-Hui Chen and Jing Wu and Marian J Loffredo and Andrew A Renshaw and Philip W. Kantoff and Anthony V. D'Amico},
  journal={JAMA oncology},
  year={2017},
  volume={3 5},
  pages={652-658}
}
Importance Several surrogates for prostate cancer-specific mortality satisfying the Prentice criteria exist, but whether these are surrogates for all-cause mortality, and how their performance compares, is unknown. Objective To ascertain and compare the performance of 4 candidate surrogates (prostate-specific antigen [PSA] failure, PSA nadir >0.5 ng/mL… CONTINUE READING